The Effectiveness of Hydroxychloroquine Versus Methotrexate in the Treatment of Frontal Fibrosing Alopecia in Routine Clinical Care: a Patient Preference Trial (FFA Trial)

Frontal fibrosing alopecia (FFA) is a type of scarring hair loss that mostly affects women and causes permanent hair loss. Two medicines, hydroxychloroquine (HCQ) and methotrexate (MTX), are often used to treat FFA, but it is not yet clear which treatment works better. This study aims to compare the effects of HCQ and MTX in everyday clinical care. Adults with FFA who choose to start either HCQ or MTX and will be followed for up to 48 weeks. The main goal is to see how well each medicine helps reduce disease activity, measured by a tool called the Frontal Fibrosing Alopecia Severity Score (FFASS) after 6 months. At each clinic visit, participants will also complete short questionnaires about symptoms, quality of life, and general well-being. By collecting this information, the study hopes to provide better evidence about how well HCQ and MTX work for FFA, which may help guide future treatment recommendations.

NCT Number	NCT07190534
Lead Sponsor	Erasmus Medical Center
Conditions	Frontal Fibrosing Alopecia, Cicatricial Alopecia
Enrollment	50 participants
Start Date	2025-11
Primary Completion	2026-11 (estimated)
Study Completion	2027-05 (estimated)
Updated on ClinicalTrials.gov	2025-09-29